Mp15-10 Immunologic Response to a Therapeutic Cancer Vaccine (Panvac): Initial Results From a Randomized Phase 2 Clinical Trial

Sanford, Thomas; Donahue, Renee N.; Jochéms, Caroline; Dolan, Rebecca; Bellfield, Sonia; Anderson, Megan E.; Singer, Eric A.; Weiss, Robert E.; Elsamra, Sammy; Jang, Thomas L.; Brancato, Sam J.; Su, Daniel; Wall, Yvonne; Gulley, James L.; Schlom, Jeffrey; Agarwal, Piyush K.

doi:10.1016/j.juro.2017.02.495

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale for this treatment modality is based on studies that have shown increased expression of MUC-1 and CEA in patients with bladder cancer [89,90]. A phase II trial assessed the efficacy of PANVAC with BCG compared to BCG monotherapy in patients with BCG-relapsing non-muscle invasive bladder cancer (Table 7) [86]. Higher rates of tumor-associated antigen response regarding CEA and MUC1 were observed with PANVAC and BCG combination compared to BCG alone.…”

Section: Vaccinesmentioning

confidence: 99%

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review

Kim

Koo

2020

Cancers

View full text Add to dashboard Cite

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have led to U.S Food and Drug Administration (FDA) approval of five novel anti-programmed cell death protein-1/ligand 1 (PD-1/L1) checkpoint inhibitors. In 2017, the anti-PD-L1 antibody atezolizumab and the anti-PD-1 antibody pembrolizumab gained approval for use in cisplatin-ineligible patients with locally advanced and metastatic UC. These approvals were based on single-arm trials, IMvigor210 (atezolizumab) and KEYNOTE-052 (pembrolizumab). Since then, additional checkpoint inhibitors, including avelumab, durvalumab, and nivolumab, have gained approval. Preliminary results suggest additional benefits with combinations of these agents in both first- and subsequent-line therapies, inferring a paradigm shift in the future treatment approach in advanced UC. Ongoing clinical trials will investigate how to utilize predictive biomarkers for optimal patient selection and to incorporate immunotherapy into earlier lines of multimodal treatment. In this comprehensive review, we summarize the evidence supporting the use of checkpoint inhibitors for patients with UC, and highlight ongoing clinical trials that are investigating novel combinations of immunotherapy in various disease settings.

show abstract

Section: Vaccinesmentioning

confidence: 99%